Brean Capital maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised its price target to $171.00 (from $119.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE